HCA HealthONE Rose announced that it has become the first hospital in Colorado to deploy Perimeter Medical Imaging’s S‑Series optical coherence tomography (OCT) system in surgical settings. The FDA‑cleared device delivers real‑time, cross‑sectional images of excised tissue at the cellular level, allowing surgeons to evaluate margins immediately during operations.
The S‑Series OCT is cleared for general tissue imaging, but it has not been specifically approved by the FDA for cancer margin assessment or for reducing re‑excision rates. Perimeter’s own disclosures emphasize that the system’s current indications are broader, and its use in oncology is still under investigation.
HCA’s adoption aligns with its broader digital‑transformation agenda, which prioritizes artificial intelligence, advanced imaging, and data‑driven decision‑making across its network of 191 hospitals and outpatient facilities. By integrating the S‑Series OCT, HCA HealthONE Rose is positioning itself to improve surgical outcomes and reduce the need for additional procedures, thereby supporting the company’s focus on quality care and cost containment.
In its most recent quarterly report, HCA Healthcare reported revenue of $19.161 billion, up 9.6% year‑over‑year, and diluted earnings per share of $6.96, a 42.6% increase from the prior year. The earnings beat analysts’ consensus of $5.65 by $1.31, driven largely by disciplined cost control and a favorable mix of high‑margin services. Revenue growth was supported by strong volume in core hospital services and an expanded payer mix, while operating margins expanded as the company leveraged scale and maintained pricing power.
Perimeter CEO Adrian Mendes said, “We are honored that HCA HealthONE Rose has chosen the S‑Series OCT. The partnership reflects our shared commitment to enhancing surgical care and demonstrates the technology’s potential to improve patient outcomes.” HCA CEO Sam Hazen added, “Our teams continue to execute our agenda at a high level, and we remain disciplined in our efforts to improve care for our patients by investing in advanced technology and training our people.”
Investors welcomed HCA’s earnings beat and the company’s upward revision of full‑year revenue guidance to $75 billion–$76.5 billion, citing strong volume growth, disciplined cost control, and the strategic value of new technologies such as the S‑Series OCT. The guidance raise signals management’s confidence in sustaining profitability while expanding its digital capabilities.
The adoption of the S‑Series OCT underscores HCA HealthONE Rose’s commitment to precision surgery and positions the hospital to potentially reduce re‑excision rates and improve patient outcomes. As HCA continues to invest in advanced imaging and AI, the technology could become a key differentiator in a competitive healthcare market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.